CANOPUS BIOPHARMA INC
We have developed an affordable, plant based cure for Hepatitis C & Dengue . We have Phase II clinical trial report confirming our product is safe & effective.
- Stage Product In Development
- Industry Biotechnology
- Location Upper Coomera, Queensland, Australia
- Currency USD
- Founded June 1997
- Employees 10
- Website canopusbiopharma.com
Company Summary
Canopus BioPharma Inc is a pharmaceutical research company that has developed a mogroside molecule that stimulates a person’s immune system, activates immune cells to attack viruses and clears viral infection very quickly. It provides no negative side effects or toxicity. We have spent over US$14.5 million over seven years and now need funds to conduct trials and obtain approval to start selling our product within 12 months for dengue fever.
Team
-
Executive Director
Peter O'Neill has been in senior management for more than 35 years and was previously Managing Director of TechStar Ltd (a public company, listed on the ASX) Has also been Managing Director of five other companies and been director on 16 company boards in his business career. He is currently a director of IN2IT Nutrition Ltd and has been Chairman of Klein Group Ltd, Fullcom Holdings Ltd and InterCamp Pty Ltd
-
Patrick PrendergastChairman of Canopus BioPharma Inc
Since licensing his first medical molecule to a major pharmaceutical corporation in 1987, he has successfully combined scientific discovery with business development and management. Patrick has academic qualifications in Microbiology & Biotechnology and acted as Chief Scientific Officer of Hollis-Eden Pharmaceutical Inc., from 1994 to 2000. Patrick was the inventor of all technologies held by HEPH which had a market capitalisation of over $300M.
Previous Investors
-
We have 76 shareholders currently in Canopus BioPharma Inc. They have contributed $14.5 million over the past 7 years.Not applicableUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.